Please ensure Javascript is enabled for purposes of website accessibility

3 Things You Need to Know About Aratana Therapeutics Before Buying

By Todd Campbell – Sep 1, 2016 at 8:28AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This biotech's focus on pets could be profit-friendly, but buying this stock does come with risks.

Image source: Aratana Therapeutics.

Aratana Therapeutics (PETX) is a biotech company developing next-generation medicine for pets. Rising spending on pet health should provide tailwinds to demand for pet medicine, but that doesn't necessarily mean that investors ought to rush out and buy Artana Therapeutics. Here are three things investors need to consider before adding this up-and-comer to their portfolios.

No. 1: No guarantees

Unlike larger pet companies such as Zoetis, Artana Therapeutics doesn't generate any meaningful product revenue and that means that its profit potential rests solely in its ability to develop drugs that pass muster with the FDA, veterinarians, and pet owners.

While companies do their best to de-risk drugs before spending heavily on R&D for them, medicines often fall shy of the mark during clinical trials and that means there's no guarantee that Artana Therapeutics will ever get into the black.

Investors were reminded painfully of the risk of clinical trials last fall when Aratana Therapeutics reported that a promising monoclonal antibody therapy for canine lymphoma failed. Share prices have rebounded since that shock, but they're still trading for less than half what they were a year ago.

PETX Chart

PETX data by YCharts.

No. 2: Revenue could be lumpy

Investors who look quickly at Aratana Therapeutics income statement may think that the company's $38 million in second quarter sales is indicative of what the company could earn in future quarters. Unfortunately, it isn't.

The vast majority of the revenue reported by Aratana Therapeutics last quarter is from an upfront payment made to by Eli Lilly & Co.'s (LLY -2.02%) animal health business, Elanco.  

Elanco paid Aratana Therapeutics a one-time upfront payment of $45 million in April to gain ex-U.S. commercialization rights to Galliprant and for co-promotion rights to Galliprant in the United States. Aratana Therapeutics recorded $38 million of that payment as collaboration revenue in Q2 and it designated the remaining $7 million to the balance sheet as a licensing and collaboration commitment.

Aratana Therapeutics could receive up to $83 million in future milestone payments, plus royalty payments and co-promotion fees, from Elanco in the future, but there's no guarantee that it will net the milestones and it only gets mid single digit to low double digit royalties on ex-U.S. sales. In the U.S., Aratana Therapeutics will receive 25% of the gross margin on sales prior to December 31, 2018 and then it will receive only a mid-single digit percentage of net sales between December 31, 2018 through 2028. 

No. 3: Flurry of activity

Eli Lilly's interest in Galliprant offers conviction, however, that Aratana Therapeutics' R&D program is on the right track. Elanco is the globe's third largest animal health company and that means that it has the resources to give Galliprant a good shot at commercial success. The deal may also indicate that other licensing agreements could happen in the future.

Among the drugs that could interest Elanco or another pet company are Entyce and Nocita. In May, the FDA approved Entyce as a therapy that can be used to stimulate appetites in dogs and in August, the FDA approved Nocita as a post-operative pain therapy. Entyce will begin generating revenue once it's launched in the first quarter of 2017 and Nocita is expected to launch before year end. 4 million dogs are treated for lack of appetite and 6 million dogs undergo painful surgery every year, according to Aratana Therapeutics' market research.

Looking ahead

Aratana Therapeutics' balance sheet boasts over $100 million in cash and that gives it some runway to establish its recently approved medications in the marketplace. If its medicines catch a foothold, then the pay-off could be big for investors. Owners are increasingly paying for human-like healthcare for their pets and last year $15.7 billion was spent on veterinary care alone. Given the markets dynamics, Aratana Therapeutics is undeniably an intriguing, albeit high-risk stock. 

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. Like this article? Follow him on Twitter where he goes by the handle @ebcapital to see more articles like this. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$323.35 (-2.02%) $-6.66
Aratana Therapeutics, Inc. Stock Quote
Aratana Therapeutics, Inc.
PETX

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.